Feature | Proton Therapy | November 06, 2017 | By Larisa Brass, MPH

Transforming the Outlook on Cancer

Why radiation oncologists should recommend proton therapy for patients diagnosed with left-sided breast cancer

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

Proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. (Image courtesy of Provision Cares Proton Therapy Center.)

The secondary cancer risk for those being treated with IMRT can be up to 10 percent greater than being treated with proton therapy. (Image courtesy of Provision Cares Proton Therapy Center.)

The secondary cancer risk for those being treated with IMRT can be up to 10 percent greater than being treated with proton therapy. (Image courtesy of Provision Cares Proton Therapy Center.)

Thirty-three. Twenty-nine. Sixty-four. These are the ages of the breast cancer patients who have walked through the Provision Cares Proton Therapy Center in Knoxville, Tenn. With decades of life ahead of them, they face a cure that could be worse than their disease.

A growing body of research shows a significant uptick in risk of post-treatment cardiac disease in women who have received conventional radiation for cancer. According to a seminal article in the New England Journal of Medicine, March 2013, women’s risk of a “major coronary event” increases by 7.4 percent for every gray (Gy) of radiation exposure to the heart. There exists no safe level of radiation, the study concluded.

For women diagnosed with cancer in the left breast, radiation treatment results in a mean dose of 10 Gy to the heart. Cardiac issues can develop within five years of treatment and continue for the rest of a woman’s life.

Another study published in JAMA Internal Medicine further quantifies the risk. Women with breast cancer who receive conventional radiation therapy stand a 0.5 percent to 3.5 percent higher chance of succumbing to a heart attack or other heart conditions. This study also explicitly stated that a higher risk exists for women with a tumor on the left side.

There is an alternative, however.

“Proton therapy completely transforms the outlook for women with breast cancer facing the long-term impacts of conventional radiation therapy,” said Allen Meek, M.D., radiation oncologist and medical director for Provision Medical Group. “With proton therapy the heart receives just 0.2 Gy of radiation exposure compared to 10 Gy with conventional photons. It’s a life-saving treatment in more ways than one.”

 

Lungs Take a Hit, Too

The breasts sit adjacent to two of the body’s most vital organs. Conventional radiation affects the lungs as well. Research shows radiation-induced pneumonitis can result from even low doses of radiation to the lungs. Recent studies suggest a critical threshold could be just 5 Gy.

In a recent pilot study of proton therapy patients, protons served up less than 0.5 Gy to the heart and just 0.6 Gy to the lungs. Nor did proton therapy cause pneumonitis or fatigue, also commonly experienced by those who receive conventional radiation. And proton therapy ranked just a grade 3 toxicity. As seen in the image to the left, proton therapy doesn’t get as near to the heart and other internal organs as X-ray therapy does. 

 

Secondary Cancer Also a Threat

Heart disease presents a unique health outcome as a result of conventional radiation therapy. The risk of secondary cancer also represents a well-documented and well-known risk following treatment.

Several studies reveal the following regarding the risk of cancer with conventional radiation versus proton therapy:

•    The risk of secondary cancer with proton therapy is 5-6 percent whereas 3-D conformal-ray therapy yields a 10 percent secondary risk of cancer. Proton therapy essentially cuts the risk of future malignancy in half.

•    A number of studies expect the secondary cancer risk to be even higher with IMRT, even as much as 15 percent, or three times that of proton therapy. Here is how it breaks down.

 

What is Proton Therapy?

Radiation therapy is the recommended and uniquely effective therapy for a majority of cancer indications. Generally, 60 percent of all cancer patients receive radiation therapy at some point during their treatment course. But the photons that destroy cancer cells cause collateral damage to healthy tissue as well. As a result, patients experience side effects such as skin burns, fatigue and the disruption of a variety of bodily processes depending on the location of the cancer. And, even more concerning, radiation therapy results in higher risk of long-term secondary chronic issues including heart and lung disease, and cancer.

Proton therapy on the other hand presents a more advanced solution to the need for radiation therapy to attack cancer growth. Proton therapy allows curative doses of radiation to be delivered to the tumor site, but reduces damage to surrounding organs and tissues.

Over the past 25 years, technology advancements and clinical trials have shown proton therapy to be an effective treatment for the majority of solid tumor cancers including prostate, breast, head and neck, brain and pediatric cancers. The U.S. Food and Drug Administration (FDA) approved proton therapy in 1988.

A piece of equipment called the ion source extracts protons from hydrogen gas. It then injects the protons into a cyclotron, which accelerates them to two-thirds the speed of light. The cyclotron ejects the protons into an energy selection system and degrader. The degrader adjusts the energy level and optimizes it for delivery to the patient. A fixed-beam or gantry system revolves around the patient, delivering the protons directly to the cancer site.

More than 100,000 patients have chosen proton therapy for their cancer treatment.

 

A Patient’s Story

An energetic woman, Kimberly Kraus, held a fast-paced job managing a restaurant. When she was diagnosed with breast cancer last year, the Provision Center for Proton Therapy helped keep her on her feet through treatment.

A grandmother and two aunts had already suffered from breast cancer, so Krause started annual mammograms early. At age 39, her mammogram showed a possibility of breast cancer. After going in for a biopsy, her doctor called her with the news — she had early stage breast cancer. He recommended six weeks of radiation in addition to lumpectomy or mastectomy.

Krause’s surgeon, George Webber, M.D., works at Knoxville Comprehensive Breast Center on the Provision campus. Each morning, a multidisciplinary task force, including pathologists, oncologists, surgeons, radiation therapists and more, meet to review patients’ files and recommend the best course of action for each individual.

“We all meet in order to provide input into a patient’s case so they can get the best possible recommendations,” said Webber. Included on that task force is Meek.

Because of the placement of Krause’s tumor, the group determined traditional radiation could affect her lungs, giving her a higher chance of developing cancer later in life.

“This is not an immediate effect,” said Meek. “What can happen is potential long-term radiation damage to the left side of the chest. This includes a higher incidence of heart disease and a higher incidence of lung cancer. Proton therapy is certainly advantageous for younger women. Many chemotherapy drugs can potentially affect the heart, also.

“The benefit in my view is that we get the same benefit for the breast, and we reduce by a considerable margin the damage to the heart and lung,” he added.

Krause found herself surprised at how proton therapy enabled her to keep up with her busy life. “It was amazing. I had minimal side effects and was able to keep the same work schedule,” she said.

 

Larisa Brass is a career journalist, freelance writer and 2014 graduate of Loma Linda University with a master’s in public health. She is currently employed by Provision Healthcare in Knoxville, Tenn.

 

General References

1.    Darby et al., “Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer,” New England Journal of Medicine 368 (2013)

 

2.    Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. “Radiation induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review.” Cancer. 2005;104(4):856-63.

 

3.    Zablotska LB, Neugut AI. “Lung carcinoma after radiation therapy in women treated with lumpectomy or mastectomy for primary breast carcinoma.” Cancer. 2003;97(6):1404-1411.

 

4.    Early Breast Cancer Trialists’ Collaborative Group. “Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials.” Lancet. 2000;335:1757-1770.

 

5.    E Yorke et al. “Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.” International Journal Radiation Oncology Biology Physics. 2005; 63: 672-682.

6.    MacDonald S. Specht M, Isako S, et al. “Prospective pilot study of proton radiation therapy for invasive carcinoma of the breast following mastectomy in patients with unfavorable anatomy – first reported clinical experience.” International Journal Radiation Oncology. 2012; 84 (Suppl 3):S113-S114. Abstract 281.

Related Content

Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation
The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

The patient’s wife changes the Optune array. Clinical trials indicate that the electrical fields emitted by Optune have the potential to lengthen the lives of patients with glioblastoma.

Feature | Radiation Oncology | November 06, 2018 | By Greg Freiherr
Approximately 11,000 professionals attended the four-day meeting of the...